US study provides 'real world' evidence about which patients with hepatitis C should be prioritised for therapy
Interferon-free treatment works well for people who inject drugs, but barriers to access remain
People who inject drugs should have access to hepatitis C treatment, expert panel recommends
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment
Cost of comprehensive global viral hepatitis prevention and treatment effort might peak at $11 billion in 2025
Medicines Patent Pool looks at hepatitis C
Hepatitis C cure associated with significant improvement in liver stiffness in people with HIV and HCV co-infection
Cirrhosis and decompensation are common among people with chronic hepatitis C
Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme
